Oragenics Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, announced it will present and host one-on-one meetings with investors at Sidoti’s Micro-Cap Virtual Investor Conference taking place May 20-21, 2026. The company’s presentation is scheduled to begin at 3:15 p.m. ET on May 21, 2026, with additional virtual one-on-one investor meetings planned throughout the conference. This event provides an opportunity for Oragenics to showcase its pipeline and engage directly with the investment community.
The company is developing brain-targeted therapeutics through proprietary intranasal delivery technology. Its lead candidate, ONP-002, is being advanced as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. The intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. Oragenics is committed to developing innovative therapies that address significant unmet medical needs in neurological care.
Investors interested in learning more can view the full press release here. For the latest news and updates relating to OGEN, visit the company’s newsroom here. More information about Oragenics is available at oragenics.com.
The Sidoti Micro-Cap Virtual Investor Conference is a key event for micro-cap companies to present to a wide audience of investors. Oragenics’ participation underscores its efforts to increase visibility and attract investment as it progresses its clinical programs. The company’s focus on concussion and mild traumatic brain injury addresses a significant medical need, with limited effective treatments currently available. The potential for its intranasal delivery platform to be applied to other neurological disorders further broadens its impact.
Oragenics' presentation at the conference will likely highlight its recent achievements and upcoming milestones, including the planned clinical trials in Australia and subsequent U.S. Phase 2b studies. The one-on-one meetings provide an opportunity for investors to ask detailed questions about the company’s science, regulatory strategy, and commercial potential. As the company advances toward clinical data readouts, investor interest may increase, making this conference an important platform for communication.